Dose Insider / FDA warning letters / BioDrive, Inc.

BioDrive, Inc.FDA warning letter, August 24, 2026

FDA letter of August 24, 2026 · posted September 22, 2026 · checked against fda.gov on November 20, 2026

On August 24, 2026, FDA sent BioDrive, Inc. of New York, NY, a warning letter about the way it made or compounded drugs, including products sold as GLP-1 drugs.

1 sectionof the Food, Drug, and Cosmetic Act cited in the letter
FDA letters on GLP-1 drugs, by yearAll 164 letters in this database; the year of this one in coral202322024112025732026, this letter78FDA letters on GLP-1 drugs,by yearAll 164 letters in this database; the year of thisone in coral202322024112025732026, this letter78

18 letters are of the same kind as this one: how a pharmacy, outsourcing facility or factory made or compounded drugs.

On this page

FDA posted the letter on September 22, 2026. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1

What does the letter say, in brief?

CompanyBioDrive, Inc.
LocationNew York, NY
Website namedNone named
Letter datedAugust 24, 2026
Posted by FDASeptember 22, 2026
Issuing officeHuman Foods Program
FDA’s subject lineDietary Supplement/Adulterated
Drugs namedproducts sold as GLP-1 drugs
Kind of letterManufacturing and compounding
Reply asked within15 working days
Close-out letterNone posted as of November 20, 2026
FDA recordMARCS-CMS 731846

What did FDA quote?

The letter quotes 1 passage. FDA quotes them as examples and says in most letters that the list is not exhaustive.1

Which parts of the law did FDA cite?

The letter cites 1 section of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.

SectionWhat it saysLetters citing it
301(a)It is prohibited to introduce an adulterated or misbranded drug into interstate commerce142

What did FDA ask the company to do?

In the letter’s own words:

FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1

Has FDA warned the seller I use?

Type a seller’s name or website. The search runs over all 164 letters in this database.

Seller check164 letters
Letters found—
Latest—

How many GLP-1 letters has FDA sent?

18 letters in this database are of the same kind as this one, how a pharmacy, outsourcing facility or factory made or compounded drugs. The chart counts letters by the quarter of their date; the quarter of this letter is marked.

Letters by quarter2023–2026
Drug named in the letter
Kind of letter
Letters—
Busiest quarter—

Which other sellers got a similar letter?

What does an FDA warning letter mean for someone buying from this seller?

FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.

FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.

A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.

What is the full text of the letter?

This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1

Read the full letter (629 words)

CMS #731846

Dear Mr. Henderson:

This letter concerns your Evolv GLP-1 Biomimetic dietary supplement. Your product labeling identifies Saccharomyces cerevisiae S288C EV-1 Peptide as a dietary ingredient. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.

Adulterated Dietary Supplements

The labeling of your Evolv GLP-1 Biomimetic dietary supplement declares “ Saccharomyces cerevisiae S288C EV-1 Peptide” (hereinafter “EV1-Peptide”) as a dietary ingredient. EV1-Peptide is a “dietary ingredient” under section 201(ff)(1)(F) of the Act [21 U.S.C. § 321(ff)(1)(F)]. EV1-Peptide is also a “new dietary ingredient” under section 413(d) of the Act [21 U.S.C. § 350b(d)] because, to the best of FDA’s knowledge, there is no information demonstrating that EV1-Peptide was marketed as a dietary ingredient in the United States before October 15, 1994.

A dietary supplement is adulterated under section 402(f)(1)(B) of the Act [21 U.S.C. § 342(f)(1)(B)] if it contains a new dietary ingredient for which there is inadequate information to provide a reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. Based on our evaluation of the relevant safety evidence, there is inadequate information to provide reasonable assurance that EV1-Peptide does not present a significant or unreasonable risk of illness or injury. Therefore, your Evolv GLP-1 Biomimetic containing the EV1-Peptide is adulterated under section 402(f)(1)(B) of the Act. The introduction of the adulterated dietary supplement into interstate commerce is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)]. Moreover, available information on the use of EV1-Peptide in products raises serious safety concerns. You submitted two new dietary ingredient notifications (NDINs) to FDA in which we determined there was inadequate information to conclude that a dietary supplement containing EV1-Peptide would reasonably be expected to be safe. Specifically, FDA identified safety concerns due to potential toxicity, which raised concerns for adverse clinical consequences. You proceeded to market Evolv GLP-1 Biomimetic despite FDA’s objections due to safety concerns.

Conclusion

This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.

Your written reply should be directed to Jamie M. Bumpas, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835, or via email at HFP-OCE-DietarySupplements@fda.hhs.gov.

Please reference CMS #713846 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.

Sincerely,

/S/

Maria S. Knirk, JD, MBA

Director, Office of Enforcement

Office of Compliance and Enforcement

Human Foods Program

Content current as of:

09/22/2026

Regulated Product(s)

Dietary Supplements

Sources

  1. FDA. Warning letter to BioDrive, Inc., August 24, 2026 (MARCS-CMS 731846). fda.gov
  2. FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
  3. FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider